Mesoporous polydopamine@CeO nanoparticles for photoacoustic-guided photothermal therapy in suppressing arthritis.

Rheumatoid arthritis (RA) is characterized by poor oxygen supply and overproduction of reactive oxygen species (ROS), thereby exacerbating synovial inflammation. We synthesized MPDA@CeO nanoparticles (NPs) by incorporating mesoporous polydopamine (MPDA) NPs and CeO for photoacoustic imaging (PAI)-guided synergistic light-controlled PTT/oxygen-boosting/ROS-eliminating therapy. Upon irradiation with a near-infrared (NIR) laser, MPDA@CeO NPs trigger photothermal conversion to eradicate inflammatory cells and release CeO, which have a catalytic activity to eliminate ROS and release oxygen. The oxygen-release and ROS-depleting efficiency was simultaneously augmented by heat to further combat the harmful environment of inflammation. We validated the therapeutic effect of MPDA@CeO and . We further applied multiwavelength PAI to observe the distribution of NPs and the change in oxygen saturation during the treatment process . The study highlights the therapeutic value of MPDA@CeO in inhibiting arthritis in RA through imaging-guided synergistic therapy.